Harmony Biosciences Holdings, Inc. (HRMY) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Harmony Biosciences Holdings, Inc.

Madrigal Pharmaceuticals, Inc.

Prestige Consumer Healthcare, Inc.

Amphastar Pharmaceuticals, Inc.

Cytokinetics, Inc.

Corcept Therapeutics, Inc.

Ultragenyx Pharmaceutical, Inc.

Xenon Pharmaceuticals, Inc.

Akero Therapeutics, Inc.

MoonLake Immunotherapeutics

Bausch Health Cos., Inc.

Why is Harmony Biosciences Holdings, Inc. ?

Strong Long Term Fundamental Strength with an average Return on Equity (ROE) of 27.07%

Healthy long term growth as Net Sales has grown by an annual rate of 40.30% and Operating profit at 65.13%
The company is Net-Debt Free

Flat results in Mar 26

ROCE(HY) Lowest at 17.86%
OPERATING PROFIT(Q) Lowest at USD 43.26 MM
PRE-TAX PROFIT(Q) Lowest at USD 39.69 MM

With ROE of 18.24%, it has a attractive valuation with a 1.76 Price to Book Value

The stock is trading at a discount compared to its peers' average historical valuations
Over the past year, while the stock has generated a return of -3.73%, its profits have risen by 9.1% ; the PEG ratio of the company is 1.2

High Institutional Holdings at 100%

These investors have better capability and resources to analyse fundamentals of companies than most retail investors.

Underperformed the market in the last 1 year

Even though the market (S&P 500) has generated returns of 22.99% in the last 1 year, the stock has hugely underperformed and has generate negative returns of -3.73% returns

Real-Time Research Report

Verdict Report

How much should you hold?

Overall Portfolio exposure to Harmony Biosciences Holdings, Inc. should be less than 10%
Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Harmony Biosciences Holdings, Inc. for you?

High Risk, Low Return

Absolute

Risk Adjusted

Volatility

Harmony Biosciences Holdings, Inc.

-3.73%

0.26

52.78%

S&P 500

22.99%

1.78

12.93%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

40.30%

EBIT Growth (5y)

65.13%

EBIT to Interest (avg)

6.67

Debt to EBITDA (avg)

0.20

Net Debt to Equity (avg)

-0.42

Sales to Capital Employed (avg)

0.82

Tax Ratio

22.55%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

100.00%

ROCE (avg)

45.85%

ROE (avg)

27.07%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

1.76

EV to EBIT

4.75

EV to EBITDA

4.24

EV to Capital Employed

3.04

EV to Sales

1.14

PEG Ratio

1.21

Dividend Yield

ROCE (Latest)

64.06%

ROE (Latest)

18.24%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bearish

RSI

Bullish

No Signal

Bollinger Bands

Mildly Bearish

Moving Averages

Bearish (Daily)

KST

Bearish

Dow Theory

Mildly Bullish

Mildly Bearish

OBV

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

5What is working for the Company

OPERATING CASH FLOW(Y)

Highest at USD 341.97 MM

CASH AND EQV(HY)

Highest at USD 1,416.26 MM

INVENTORY TURNOVER RATIO(HY)

Highest at 40.24 times

-11What is not working for the Company

ROCE(HY)

Lowest at 17.86%

OPERATING PROFIT(Q)

Lowest at USD 43.26 MM

PRE-TAX PROFIT(Q)

Lowest at USD 39.69 MM

NET PROFIT(Q)

Fallen at -28.69%

Here's what is working for Harmony Biosciences Holdings, Inc.

Operating Cash Flow

Highest at USD 341.97 MM and Grown

In each year in the last three years

MOJO Watch

The company has generated higher cash revenues from business operations

Operating Cash Flows (USD MM)

Cash and Eqv

Highest at USD 1,416.26 MM

in the last six Semi-Annual periods

MOJO Watch

Short Term liquidity is improving

Cash and Cash Equivalents

Inventory Turnover Ratio

Highest at 40.24 times

in the last five Semi-Annual periods

MOJO Watch

Company has been able to sell its inventory faster

Inventory Turnover Ratio

Here's what is not working for Harmony Biosciences Holdings, Inc.

Operating Profit

Lowest at USD 43.26 MM

in the last five periods

MOJO Watch

Near term Operating Profit trend is negative

Operating Profit (USD MM)

Pre-Tax Profit

Lowest at USD 39.69 MM

in the last five periods

MOJO Watch

Near term Pre-Tax Profit trend is negative

Pre-Tax Profit (USD MM)

Pre-Tax Profit

Fallen at -30.59%

Year on Year (YoY)

MOJO Watch

Near term Pre-Tax Profit trend is negative

Pre-Tax Profit (USD MM)

Net Profit

Fallen at -28.69%

Year on Year (YoY)

MOJO Watch

Near term Net Profit trend is negative

Net Profit (USD MM)

Non Operating Income

Highest at USD 0.14 MM

in the last five periods

MOJO Watch

Increased income from non business activities may not be sustainable

Non Operating income